FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bob van Oosten

Research Profile

Disorders

Concepts & Ideas

Magnetic Resonance Imaging

Anatomy

Chemicals & Drugs

Co-author Network

Publications

TOP 3
José Manuel Valdueza; Bob W van Oosten; Florian Doepp; Friedemann Paul; Klaus Schmierer; Stephan J Schreiber; Mike P Wattjes
What went wrong? The flawed concept of cerebrospinal venous insufficiency.
Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Femke Visser; Mike P Wattjes; Wim H J P Linssen; Petra J W Pouwels; Bob W van Oosten
Tumefactive multiple sclerosis lesions under fingolimod treatment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bob van Oosten (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: José Manuel Valdueza; Bob W van Oosten; Florian Doepp; Friedemann Paul; Klaus Schmierer; Stephan J Schreiber; Mike P Wattjes
What went wrong? The flawed concept of cerebrospinal venous insufficiency.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2013;33(5):657-68.
2013: Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
The New England journal of medicine 2013;368(17):1658-9.
2012: Femke Visser; Mike P Wattjes; Wim H J P Linssen; Petra J W Pouwels; Bob W van Oosten
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Neurology 2012;79(19):2000-3.
2012: Arjan Malekzadeh; Heleen Beckerman; Marinus A Blankenstein; Vincent de Groot; Bob W van Oosten; Charlotte E Teunissen
Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.
Methods (San Diego, Calif.) 2012;56(4):508-13.
2011: Mike P Wattjes; Bob W van Oosten; Wolter L de Graaf; Alexandra Seewann; Joost C J Bot; René van den Berg; Bernard M J Uitdehaag; Chris H Polman; Frederik Barkhof
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study.
Journal of neurology, neurosurgery, and psychiatry 2011;82(4):429-35.
2011: A Vennegoor; Mike P Wattjes; E T L van Munster; R L Kriekaart; Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Neurology 2011;76(6):574-6.
2010: Joep Killestein; Anke Vennegoor; Eva M Strijbis; Alexandra Seewann; Bob W van Oosten; Bernard M J Uitdehaag; Chris H Polman
Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
Annals of neurology 2010;68(3):392-5.
2009: Richard Daniëls; Jeroen J G Geurts; Joost C J Bot; Wouter J Schonewille; Bob W van Oosten
Steroid-responsive edema in CAA-related inflammation.
Journal of neurology 2009;256(2):285-6.
2007: Bernard Uitdehaag; Brechtje Jelles; Joep Killestein; Bob W van Oosten; Chris H Polman
[Immunomodulatory therapy in multiple sclerosis].
Nederlands tijdschrift voor geneeskunde 2007;151(25):1435; author reply 1435-6.
2006: Jessica M Nielsen; Frederik Barkhof; Bob W van Oosten; Chris H Polman
The role of spinal cord imaging in the diagnosis of multiple sclerosis.
Nature clinical practice. Neurology 2006;2(5):283-6; quiz 287.
2006: Keith S Cover; Hugo Vrenken; Jeroen J G Geurts; Bob W van Oosten; Brechtje Jelles; Chris H Polman; Cornelis Stam; Bob W van Dijk
Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG.
NeuroImage 2006;29(3):783-8.
2005: Bob W van Oosten; J Killestein; Ch Polman
Effect of rimonabant on weight reduction and cardiovascular risk.
Lancet 2005;366(9483):368-9; author reply 369-70.
2004: Bob W van Oosten; Joep Killestein; E M H Mathus-Vliegen; Chris H Polman
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):330-1.
1999: Anette H H van Boxel-Dezaire; S C Hoff; Bob W van Oosten; Cornelis L Verweij; A M Dräger; H J Adèr; Johannes C van Houwelingen; Frederik Barkhof; Chris H Polman; Lex Nagelkerken
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
Annals of neurology 1999;45(6):695-703.
1999: Marianne A A van Walderveen; Luc Truyen; Bob W van Oosten; Jonas A Castelijns; Geert Lycklama à Nijeholt; Jan-Hein T M van Waesberghe; Chris H Polman; Frederik Barkhof
Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.
Archives of neurology 1999;56(3):345-51.
1998: Bob W van Oosten; Luc Truyen; Frederik Barkhof; Chris H Polman
Choosing drug therapy for multiple sclerosis. An update.
Drugs 1998;56(4):555-69.
1998: Bob W van Oosten; Frederik Barkhof; Petra E T Scholten; B M von Blomberg; Herman J Adèr; Chris H Polman
Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.
Archives of neurology 1998;55(6):793-8.
1997: Bob W van Oosten; Bernard Uitdehaag; Frederik Barkhof; H P Hartung; John Wagstaff; Chris H Polman
Interleukin-2 therapy does not exacerbate multiple sclerosis.
Neurology 1997;49(2):633-4.
1997: Bob W van Oosten; M Lai; S Hodgkinson; Frederik Barkhof; D H Miller; I F Moseley; Alan J Thompson; P Rudge; A McDougall; J G McLeod; Herman J Adèr; Chris H Polman
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
Neurology 1997;49(2):351-7.
1997: Martijn Rep; Bob W van Oosten; Marijke Th L Roos; Herman J Adèr; Chris H Polman; René A W van Lier
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
The Journal of clinical investigation 1997;99(9):2225-31.
1997: Tom W J Huizinga; Rudi G J Westendorp; E L Bollen; Vivian Keijsers; BM Brinkman; JA Langermans; Ferdinand C Breedveld; Cornelis L Verweij; L van de Gaer; L Dams; J B A Crusius; A García-Gonzalez; Bob W van Oosten; Chris H Polman; A S Peña
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.
Journal of neuroimmunology 1997;72(2):149-53.
1996: Bob W van Oosten; Frederik Barkhof; Luc Truyen; J B Boringa; Frits W Bertelsmann; B M von Blomberg; J N Woody; H P Hartung; Chris H Polman
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
Neurology 1996;47(6):1531-4.
1996: Luc Truyen; Jan-Hein T M van Waesberghe; Marianne A A van Walderveen; Bob W van Oosten; Chris H Polman; Otto R Hommes; H J Adèr; Frederik Barkhof
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.
Neurology 1996;47(6):1469-76.
1996: Bob W van Oosten; M Lai; Frederik Barkhof; D H Miller; I F Moseley; A J Thompson; S Hodgkinson; Chris H Polman
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(6):339-42.
1996: Bob W van Oosten; Martijn Rep; René A W van Lier; P E Scholten; B M von Blomberg; K W Pflughaupt; H P Hartung; H J Adèr; Chris H Polman
A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.
Journal of neuroimmunology 1996;66(1-2):49-55.
1995: J B A Crusius; Amado Salvador Peña; Bob W van Oosten; G Bioque; A Garcia; C D Dijkstra; C H Polman
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis.
Lancet 1995;346(8980):979.
1995: Bob W van Oosten; Luc Truyen; Frederik Barkhof; Chris H Polman
Multiple sclerosis therapy. A practical guide.
Drugs 1995;49(2):200-12.